Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Primary Hepatocellular Carcinoma (HCC)
The purpose of this study is to determine efficacy of SB injection in Hepatocellular Carcinoma (HCC).
Hepatocellular Carcinoma
DRUG: SB injection
Evaluating Tumor Response Rate, 4 Months
Pain Scores on the Visual Analog Scale, 4 Months|Number of Participants with Adverse Events as a Measure of Safety and Tolerability scale, 4 Months|Determine duration of response rate by measuring time to progression, 4 Months
All eligible patients will receive SB injection therapy for 6 cycles (14\~21 days for each cycle). Efficacy wll be evaluated every 3 cycles.